Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OGN with free AI briefings, catalyst countdowns, and dilution alerts.

OGN · Organon & Co.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5B Cash on Hand
CF+ Cash Runway
Follow OGN by email Get an email when OGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OGN, unsubscribe in one click. Privacy

📣 What OGN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Mometasone
FDA approved Apr 1987 · Elocon (discontinued)
Rhinitis, Allergic, Seasonal Phase 4 · NCT00070707 Completed
Tapinarof
FDA approved May 2022 · Vtama
Plaque Psoriasis Phase 3 · NCT03983980 Completed
Montelukast
FDA approved Feb 1998 · Singulair
Allergic Rhinitis Phase 3 · NCT01673620 Completed
Etonogestrel
FDA approved Jul 2006 · Implanon
Benign Prostatic Hyperplasia (BPH) Phase 2 · NCT00651807 Terminated
Ganirelix
FDA approved Jul 1999 · Ganirelix Acetate
Pregnancy N/A · NCT00703014 Completed
Gonapeptyl® Ovarian Stimulation Phase 4 · NCT06175832 Recruiting
VTAMA (tapinarof) cream, 1% Psoriasis Phase 4 · NCT05680740 Completed
Puregon® Ovarian Stimulation Phase 4 · NCT06175832 Recruiting
Orgalutran® Ovarian Stimulation Phase 4 · NCT06175832 Recruiting
Norethindrone Breakthrough Bleeding Phase 4 · NCT04047875 Completed
Etoricoxib Acute Gout Phase 4 · NCT00142558 Completed
Elonva® Ovarian Stimulation Phase 4 · NCT06175832 Recruiting
Comparator: indomethacin 75 mg sustained… Acute Gout Phase 4 · NCT00142558 Completed
Desogestrel Ovarian Stimulation Phase 4 · NCT06175832 Recruiting
Atozet 10/40 mg or 10/80 mg Atherosclerotic Cardiovascular Disease Phase 4 · NCT05761444 Completed
Albuterol Rhinitis, Allergic, Seasonal Phase 4 · NCT00070707 Completed

Also used in these trials (approved or third-party drugs, not OGN's own candidates): Atorvastatin Calcium, Ezetimibe, Montelukast Sodium, Pembrolizumab, Trastuzumab, Leucovorin, Triptorelin, Progesterone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OGN holds $1.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OGN files for a raise →

👥 Who Owns OGN

Insiders 0.3% Institutions (777 holders) 86.7% Public and other holders 13%
HolderTypeShares% of sharesAs of
Pentwater Capital Management LP Institution (13G, 5%+) 18,100,000 6.89% 2026-06-30
Vanguard Portfolio Management Institution (13G, 5%+) 15,161,710 5.77% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 13,717,181 5.22% 2026-03-31
Matthew M Walsh
Chief Financial Officer · +43,094 options
Insider 212,746 0.08% 2026-03-31
Joseph T. Jr. Morrissey
CEO · +87,489 options
Insider 153,316 0.06% 2026-11-13
Rachel A Stahler
Chief Information Officer · +24,625 options
Insider 116,105 0.04% 2026-03-31
Aaron Falcione
Chief Human Resources Officer · +22,386 options
Insider 101,431 0.04% 2026-03-31
Kirke Weaver
Gen. Counsel & Corp. Secy. · +24,625 options
Insider 92,639 0.04% 2026-03-31
Vittorio Nisita
Head of Global Business Svcs · +16,790 options
Insider 70,619 0.03% 2026-03-31
Daniel Karp
Executive VP, Corp. Dev. · +13,432 options
Insider 69,548 0.03% 2026-03-31
Ferreira Juan Camilo Arjona
Head of R&D & CMO
Insider 41,565 0.02% 2026-11-07
Juliana Papa Drinane
Head of Mfg & Supply · +51,723 options
Insider 35,239 0.01% 2026-11-13

Share count 262,621,584 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full OGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.